📊 MLTX Key Takeaways
Is MoonLake Immunotherapeutics (MLTX) a Good Investment?
MoonLake is a pre-revenue biotech company burning $66.3M per operating period with losses accelerating (EPS down 86.8% YoY), indicating worsening operational efficiency. While the $298.5M cash position provides runway for approximately 18-20 months, the fundamental deterioration in losses combined with zero revenue generation presents a high-risk financial profile dependent entirely on future clinical success.
MoonLake is a pre‑revenue biotech with substantial operating losses and deeply negative ROE/ROA, but carries a strong liquidity position (9.27x current ratio) and sizeable cash balance of $334.5M. At the current burn rate (~$196M OCF), cash provides roughly 18–20 months of runway with modest leverage (0.24x D/E). Without near‑term revenue visibility, fundamentals hinge on R&D execution and non‑dilutive funding progress, with dilution risk if timelines slip.
MoonLake Immunotherapeutics Key Strengths (MLTX)
- Strong cash position of $298.5M (75% of total assets) provides operational runway
- Excellent liquidity with 8.60x current and quick ratios indicating ability to meet short-term obligations
- Moderate leverage with 0.39x debt-to-equity ratio, manageable debt burden
- Robust liquidity and cash runway (9.27x current ratio, $334.5M cash)
- Low leverage (0.24x D/E) with minimal capex needs
- Slight YoY improvement in net loss alongside disciplined balance sheet
MLTX Stock Risks: MoonLake Immunotherapeutics Investment Risks
- No revenue generation; company remains pre-commercial with zero sales
- Accelerating operating losses ($70M in latest period) with net loss worsening 86.8% YoY on EPS basis
- Negative cash burn of $66.3M per period exhausts cash runway in approximately 18-20 months without revenue inflection or additional funding
- Negative ROE (-27.4%) and ROA (-17.4%) indicate shareholder value destruction
- All profitability metrics unavailable or negative; no evidence of path to positive unit economics
- No revenue/gross margin visibility; ongoing pre-commercial stage
- High cash burn and large operating losses driving negative ROE/ROA
- Potential dilution/refinancing need within ~2 years absent revenue or partnerships
Key Metrics to Watch
- Operating cash burn rate and cash runway depletion timeline
- Revenue recognition milestones and commercial product launch timeline
- Quarterly net losses trend and operating margin trajectory
- Quarterly operating cash flow (burn) and cash runway
- R&D expense trend versus clinical milestones toward first revenue
MoonLake Immunotherapeutics (MLTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.60x current ratio provides a solid financial cushion.
MLTX Profit Margin, ROE & Profitability Analysis
MLTX vs Healthcare Sector: How MoonLake Immunotherapeutics Compares
How MoonLake Immunotherapeutics compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MoonLake Immunotherapeutics Stock Overvalued? MLTX Valuation Analysis 2026
Based on fundamental analysis, MoonLake Immunotherapeutics has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MoonLake Immunotherapeutics Balance Sheet: MLTX Debt, Cash & Liquidity
MLTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: MoonLake Immunotherapeutics's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.73 indicates the company is currently unprofitable.
MLTX Revenue Growth, EPS Growth & YoY Performance
MoonLake Immunotherapeutics Dividends, Buybacks & Capital Allocation
MLTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for MoonLake Immunotherapeutics (CIK: 0001821586)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MLTX
What is the AI rating for MLTX?
MoonLake Immunotherapeutics (MLTX) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MLTX's key strengths?
Claude: Strong cash position of $298.5M (75% of total assets) provides operational runway. Excellent liquidity with 8.60x current and quick ratios indicating ability to meet short-term obligations. ChatGPT: Robust liquidity and cash runway (9.27x current ratio, $334.5M cash). Low leverage (0.24x D/E) with minimal capex needs.
What are the risks of investing in MLTX?
Claude: No revenue generation; company remains pre-commercial with zero sales. Accelerating operating losses ($70M in latest period) with net loss worsening 86.8% YoY on EPS basis. ChatGPT: No revenue/gross margin visibility; ongoing pre-commercial stage. High cash burn and large operating losses driving negative ROE/ROA.
What is MLTX's revenue and growth?
MoonLake Immunotherapeutics reported revenue of N/A.
Does MLTX pay dividends?
MoonLake Immunotherapeutics does not currently pay dividends.
Where can I find MLTX SEC filings?
Official SEC filings for MoonLake Immunotherapeutics (CIK: 0001821586) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MLTX's EPS?
MoonLake Immunotherapeutics has a diluted EPS of $-0.98.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is MLTX's fundamental grade?
Based on our AI fundamental analysis in May 2026, MoonLake Immunotherapeutics has a C grade with 68% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is MLTX stock overvalued or undervalued?
Valuation metrics for MLTX: ROE of -27.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is MLTX's AI grade for 2026?
Our dual AI analysis gives MoonLake Immunotherapeutics a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MLTX's free cash flow?
MoonLake Immunotherapeutics's operating cash flow is $-66.3M, with capital expenditures of $0.0.
How does MLTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -27.4% (avg: 15%), current ratio 8.60 (avg: 2).